⚔️ Head-to-head

Retatrutide vs Survodutide

Pep lines up the two side by side — verdict, mechanism, and the dimensions that actually differ — so you can see where each one wins.

By MrPepTalks Editorial · Updated 2026-07-08

Retatrutide vs Survodutide

Retatrutide

LY3437943

promising

🏆 Wins on clinical stage

Survodutide

BI 456906

promising
Retatrutide
Dimension
Survodutide
Triple agonist — engages GLP-1, GIP, and glucagon receptors
Receptor targets
Dual agonist — engages GLP-1 and glucagon receptors
Studied in trials for obesity and metabolic outcomes
Commonly researched for
Studied in trials for obesity and for liver conditions such as MASH
Reached later-stage (Phase 3) trials
🏆 winner
Clinical stage
Reported in mid-stage (Phase 2) trials, with later-stage work in progress
Phase 2 trials reported changes in body weight over the study period
What the trials reported
Phase 2 trials reported changes in body weight and, separately, liver-fat measures
Gastrointestinal complaints such as nausea were commonly reported in trials
Reported side-effect profile
Gastrointestinal complaints such as nausea were commonly reported in trials
Investigational — not FDA-approved; sold only as a research-grade compound
Regulatory status
Investigational — not FDA-approved; sold only as a research-grade compound
No approved consumer product; research-use supply only
Availability
No approved consumer product; research-use supply only
Broader public trial readouts to date
🏆 winner
Depth of public evidence
Narrower public trial readouts, with more data still pending
Promising (still investigational)
🏆 winner
Our verdict
Unproven (earlier-stage, data still emerging)
Retatrutide data sheetThe terse reference: facts, forms, and Pep's verdict.Survodutide data sheetThe terse reference: facts, forms, and Pep's verdict.
Send it to me →

No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.